Trial Profile

REPLICA: Real Patient Life Treatment With Cabozantinib in Patients With Advanced or Metastatic RCC: A Descriptive and Prospective Non-Interventional Study

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms REPLICA
Sponsors Ipsen

Most Recent Events

05 Dec 2025 Planned End Date changed from 1 Sep 2027 to 31 Mar 2027.
05 Dec 2025 Status changed from recruiting to active, no longer recruiting.
29 Sep 2025 Planned End Date changed from 30 Jun 2026 to 1 Sep 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com